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Natural killer (NK) cells have been reported to control
adaptive immune responses that occur in lymphoid
organs at the early stages of immune challenge.
The physiological purpose of such regulatory activity
remainsunclear,because itgenerallydoesnotconfera
survival advantage.We found thatNKcells specifically
eliminated activated CD4+ T cells in the salivary gland
during chronicmurine cytomegalovirus (MCMV) infec-
tion. This was dependent on TNF-related apoptosis
inducing ligand (TRAIL) expression by NK cells.
Although NK cell-mediated deletion of CD4+ T cells
prolonged the chronicity of infection, it also con-
strained viral-induced autoimmunity. In the absence
of this activity, chronic infection was associated with
a Sjogren’s-like syndrome characterized by focal lym-
phocytic infiltration into the glands, production of au-
toantibodies, and reduced saliva and tear secretion.
Thus, NK cells are an important homeostatic control
that balances the efficacy of adaptive immune re-
sponses with the risk of developing autoimmunity.
INTRODUCTION
Natural killer (NK) cells, a prototypical component of innate im-
munity, are rapidly recruited to sites of cellular transformation
or intracellular infection (Vivier et al., 2008) and, depending on
a delicate balance of signals mediated by activating and inhibi-
tory receptors, promptly mediate cytotoxic activities or cytokine
secretion (Lanier, 2008). Additional functions of NK cells have
been uncovered in recent years that demonstrate their role in
immunoregulation (Biron, 2012; Degli-Esposti and Smyth,
2005). Evidence points to immunoregulatory functions being eli-
cited in the early stages of the immune response (Andrews et al.,646 Immunity 41, 646–656, October 16, 2014 ª2014 Elsevier Inc.2010; Lang et al., 2012; Lee et al., 2009; van Dommelen et al.,
2006; Waggoner et al., 2012), but very little is known about the
potential activities of NK cells at later times, especially in chronic
inflammatory pathologies associated with persistent viral infec-
tions. Furthermore, the role of NK cells in tissue-specific immune
responses is unknown.
There has been a growing appreciation of the influence of NK
cells on the adaptive immune response. NK cell depletion prior
to infection enhances the CD8+ T cell response against lympho-
cytic choriomeningitis virus (LCMV) and murine cytomegalovirus
(MCMV) (Andrews et al., 2010; Su et al., 2001). In the case of
LCMV, the elimination of CD8+ T cells by NK cells involves 2B4,
natural killer group 2, member D (NKG2D) and perforin-mediated
activities (Lang et al., 2012; Waggoner et al., 2010). In addition,
activated NK cells can eliminate activated CD4+ T cells in a per-
forin-mediated manner and thereby affect the CD8+ T cell func-
tions required for effective viral clearance (Waggoner et al.,
2012). In contrast, there is no evidence for the direct regulation
of the CD8+ T cell response by NK cells during MCMV infection.
Instead, the elimination of infected dendritic cells by NK cells
limits the activation of T cells (Andrews et al., 2010). In other set-
tings, such as transplantation or the development of autoimmu-
nity, NK cells also limit T cell activation, though the mechanisms
have yet to be clearly defined (Crome et al., 2013). The role of NK
cells in chronic inflammatory situations, especially in nonlym-
phoid tissues, is poorly defined and indeed most published
studies have focused on tissue-specific T cell responses (Burzyn
et al., 2013; Heath andCarbone, 2013;Mueller et al., 2013). As far
as NK cells are concerned, the focus has been on responses eli-
cited in lymphoid organs in the early stages of immune challenge
(Andrews et al., 2010; Lee et al., 2009; Su et al., 2001; van Dom-
melen et al., 2006; Waggoner et al., 2012). Furthermore, in the
settings examined to date, NK cells contribute to viral persistence
or pathology, which seems contradictory and leaves the physio-
logical purpose of these activities unclear.
Here, we define a novel interaction between NK cells and CD4+
T cells during chronic viral infection in vivo. This interaction occurs
in a nonlymphoid tissue, specifically involves TRAIL-expressing
Immunity
NK Cells Balance Viral Persistence and AutoimmunityNK cells, and results in the elimination of activated CD4+ T cells.
Notably, we show that via these interactions, NK cells balance the
efficacy of adaptive immune responses with the development of
autoimmunity.
RESULTS
TRAIL+ NKCells Accumulate in the SalivaryGland during
Chronic CMV Infection
Chronic MCMV infection in the salivary glands (SGs) of BALB/c
mice is controlled by CD4+ T cells, independently of CD8+
T cells (Andrews et al., 2010). Interestingly, we found that the
number of NK cells in the SGs of BALB/c mice increased signif-
icantly after MCMV infection (Figure 1A). The SG-resident NK
cells in naive BALB/c mice showed a phenotype similar to that
reported previously for C57BL/6 mice (Figure 1B, filled histo-
gram; Tessmer et al., 2011). After MCMV infection, NK cells
localized to the SGs expressed increased amounts of cell sur-
face markers associated with maturation and/or activation (Fig-
ure 1B, bold line). Of particular interest was the finding that, in the
SGs, NK cells expressing TRAIL increased after MCMV infection
(Figures 1C and 1D); this was not observed in other tissues (Fig-
ure S1 available online). A subset of NK cells that reside in the
liver express TRAIL, as described previously (Takeda et al.,
2005); however, despite an increase in total NK cell numbers dur-
ing acute infection (Figure 1E), the absolute number of hepatic
TRAIL+ NK cells remained unaffected (Figure 1F). Indeed, at
the peak of NK cell expansion (day 10 pi), the frequency of
TRAIL+ NK cells in the liver declined (Figure S1B). In the SGs,
TRAIL was exclusively expressed on NK cells and not on other
lymphocyte populations localizing to this tissue after MCMV
infection (Figures S1C–S1G). Altogether these data demonstrate
that a population of NK cells expressing TRAIL accumulates spe-
cifically in the SGs during chronic MCMV infection.
TRAIL Modulates the Control of Chronic Infection in the
Salivary Glands
TRAIL has the capacity to induce apoptosis of some typesof cells
(Falschlehner et al., 2009). The specific accumulation of TRAIL+
NK cells in the SGs may therefore be a mechanism to eliminate
infected cells, and thus control MCMV infection at this site. We
tested this possibility by infecting BALB/c mice that were TRAIL
deficient (Trail–/–). Although MCMV replication in the SGs of
Trail–/– mice was initially similar to that of wild-type (WT) mice,
by day 25 pi MCMV titers in TRAIL-deficient mice were signifi-
cantly lower than those in WT mice and continued to decrease
faster, so that by day 32 they were close to the limit of detection
in Trail–/– mice (Figure 2A). By day 40 pi, virus was not detectable
in either WT or Trail–/– mice (data not shown). Analysis of viral
loads in the peripheral organs of Trail–/– mice indicated that, in
the absence of TRAIL, virus control was not hindered; indeed, it
was slightly enhanced at later time points (Figure S2). TRAIL me-
diates its effects via engagement of the death receptor 5 (DR5) in
mice (Wuet al., 1999).WhenBALB.Dr5–/–micewere infectedwith
MCMV, control of the virus in the SGs was improved to a similar
extent to that which occurred in Trail–/– mice (Figure 2B). These
findings indicate that the accumulation of TRAIL+ NK cells in
the SGs does not contribute to the control of MCMV, but rather
delays the clearance of this virus.CD4+ T Cells Interact with TRAIL+ NK Cells during
Chronic Infection
CD4+ T cells mediate control of MCMV in the SGs (Andrews
et al., 2010). Examination of SG tissue sections from MCMV-in-
fected mice demonstrated that NK cells were in close proximity
to CD4+ T cells after MCMV infection (Figure 3A), with 30.56% ±
3.47% of NK cells making contact with CD4+ T cells. Further-
more, a large proportion of the CD4+ T cells infiltrating the SGs
expressed DR5, the receptor for TRAIL (Figure 3B). These find-
ings raised the possibility that NK cells might interact with
CD4+ T cells within the SGs and thus influence the adaptive im-
mune response to MCMV infection.
To explore this possibility, we compared the CD4+ T cell
response in WT mice with that in TRAIL-deficient mice. The num-
ber of CD4+ T cells in the SGs ofMCMV-infected Trail–/– mice was
similar to that ofWTmice at day 10pi, but by day 18pi significantly
larger numbers of CD4+ T cells were present in the SGs of Trail–/–
mice (Figure 3C), as was the number of CD4+DR5+ T cells (Fig-
ure 3D). DR5 was expressed by activated CD4+ T cells, defined
as displaying high amounts of CD44 (Figure 3E), and correlated
with degranulation, measured by CD107a staining (Figure 3F).
The numbers of CD4+ T cells coexpressing CD44hi and DR5 (Fig-
ure 3G) or CD107a and DR5 were both elevated in the absence of
TRAIL (Figure 3H). Therefore, TRAIL expression directly influ-
enced the number of activated CD4+ T cells present in the SGs.
Interactions between NK Cells and CD4+ T Cells
Involve NKG2D
Both CD4+ (Figure 3B) andCD8+ (data not shown) T cells express
the TRAIL receptor during MCMV infection. However, the fre-
quency of DR5+CD8+ T cells is 5-fold lower than that of
DR5+CD4+ T cells in the SGs (7.68% ± 0.87% versus
27.53% ± 1.39% at day 18 pi). The CD8+ T cell population is
not affected by the presence of TRAIL+ NK cells, suggesting
that additional interactions are required for the elimination of
DR5+CD4+ T cells. NKG2D is an activating NK cell receptor
whose ligands are expressed on infected or stressed cells (Rau-
let et al., 2013). NKG2D expression was increased on 40% of
SG NK cells during the course of MCMV infection (Figure 4A)
and at higher amounts on TRAIL+ NK cells (Figure 4B). In addition
to stressed and infected cells, NKG2D ligands can be expressed
on activated T cells (Cerboni et al., 2007; Rabinovich et al., 2003).
When the expression of NKG2D ligands was evaluated on T cells
from the SGs of MCMV-infected mice, it was found to be largely
restricted to the CD4+ T cell population (Figure 4C). More than
40% of CD4+ T cells expressed NKG2D ligands at day 18 pi,
compared to less than 10% of CD8+ T cells (Figure 4D). Expres-
sion of NKG2D ligands on CD4+ T cells was restricted to the
CD44hi subset; more than half of these cells also coexpressed
the TRAIL receptor DR5 (Figure 4E). These data show that during
MCMV infection, NKG2D ligands are preferentially expressed on
CD4+ T cells and probably contribute to interactions with
NKG2D+TRAIL+ NK cells in the SGs.
TRAIL+ NK Cells Limit Antiviral CD4+ T Cell Responses
Depletion experiments were performed in Trail–/– mice to deter-
mine whether CD4+ T cells were required for viral control in the
absence of TRAIL. TRAIL-deficient mice were specifically
depleted of CD4+ or CD8+ T cells from day 9 pi and viral titers inImmunity 41, 646–656, October 16, 2014 ª2014 Elsevier Inc. 647
Figure 1. TRAIL+ NK Cells Accumulate in the SGs during Chronic MCMV Infection
(A) NK cells were enumerated in the SGs after infection with MCMV-K181 (53 103 PFU/mouse). Data are pooled from four independent experiments and plotted
as mean ± SEM (n = 16/time point).
(B) Expression of various cell surface markers on NK cells isolated from the SGs of MCMV-infected mice is shown. The histograms depict NK cells from
uninfected mice (gray filled histograms) and MCMV-infected mice at day 18 pi (open black line histograms). The data are representative of a minimum of two
independent experiments (n = 3–4 mice/experiment).
(C) Expression of TRAIL on NK cells present in the SGs after MCMV infection was measured by flow cytometry. The data are representative of four independent
experiments (n = 4 mice/experiment).
(D) Absolute numbers of TRAIL+ NK cells present in the SGs of MCMV-infected mice. Data are pooled from four independent experiments and plotted as mean ±
SEM (d0 n = 8, d10 n = 16, d18 n = 16).
(E and F) Number of NK cells (E) and number of TRAIL+ NK cells (F) in the liver at various times pi. Data are pooled from at least two independent experiments with
three to four mice each and plotted as mean ± SEM (d0 n = 11, d10 n = 12, d18 n = 16, d25 n = 8).
*p < 0.05, ***p < 0.001. p values for (A), (D), and (E) were obtained using a two-tailed Mann-Whitney test. See also Figure S1.
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NK Cells Balance Viral Persistence and Autoimmunitythe SGsmeasured at day 25pi. Althoughdepletion of CD8+ T cells
had no impact on the viral loadwithin the SGs, the viral loadwithin
the SGs of Trail–/– mice depleted of CD4+ T cells was significantly648 Immunity 41, 646–656, October 16, 2014 ª2014 Elsevier Inc.higher (Figure 5A). Taken together, these data suggest that TRAIL
expression by NK cells accumulating in the SGs acts to eliminate
CD4+ T cells and consequently delays viral clearance.
Figure 2. TRAIL Limits theControl of ChronicMCMV Infection in SGs
(A) Viral loads in the SGs of BALB/c (WT) and BALB.Trail–/– (Trail–/–) mice in-
fectedwith 104 PFU ofMCMV-K181. SGswere collected at the indicated times
and viral titers determined by plaque assay. Data are pooled from at least two
independent experiments with at least three mice/group and plotted as
mean ± SEM (d4 n = 6, d10 n = 9, d18 n = 9, d25 n = 13, d32 n = 7 for both WT
and Trail–/–).
(B) Viral loads in the SGs of BALB/c (WT) and BALB.Dr5–/– (Dr5–/–) mice in-
fected with 104 PFU of MCMV-K181. Data are pooled from at least two in-
dependent experiments with at least three mice/group and plotted as mean ±
SEM (d4, WT n = 8 and Dr5–/– n = 7; d10, WT n = 8 and Dr5–/– n = 6; d18, d25,
and d32, WT n = 12 and Dr5–/– n = 10).
**p < 0.01, ***p < 0.001. p values were obtained using a two-tailed Mann-
Whitney test. See also Figure S2.
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NK Cells Balance Viral Persistence and AutoimmunityTo demonstrate that NK cells restrain the CD4+ T cell
response, we depleted NK cells after infection. For these exper-
iments we made use of the BALB.B6-CT6 (CT6) congenic
mouse strain (Scalzo et al., 1999). This mouse strain has the
advantage that it expresses the NK1.1 receptor (absent in
BALB/c mice), but like the BALB/c strain lacks the Ly49H acti-
vating NK cell receptor. CT6 mice were infected with MCMV,
and NK cells were specifically depleted using the anti-NK1.1
antibody PK136 from day 9 pi. Mice depleted of NK cells had
a significantly lower viral burden in the SGs at day 25 pi
compared to nondepleted mice (Figure 5B). Furthermore, the
percentage and total number of DR5+CD4+ T cells localized to
the SGs was significantly increased in the absence of NK cells
(Figures 5C and 5D). In an additional strategy, we adoptively
transferred WT naive NK cells into TRAIL-deficient mice at day
4 pi and assessed viral loads in the SGs at day 25 pi. The transferof WT NK cells into TRAIL-deficient mice resulted in a significant
increase in the viral burden within the SGs (Figure 5E). Viral loads
in the SGs were not altered when TRAIL-deficient NK cells were
transferred into TRAIL-deficient mice or when WT NK cells were
transferred into WT hosts (Figure 5E). Notably, transferring WT
TRAIL-sufficient NK cells into Trail–/– hosts resulted in a signifi-
cant decrease in the number of DR5+CD4+ T cells (Figure 5F),
clearly demonstrating a causative impact of NK cell TRAIL on
this phenotype. Together these data establish that NK cells limit
the antiviral CD4+ T cell response within the SGs through a
TRAIL-dependent mechanism.
Infection-Induced Autoimmunity Is Constrained in a
TRAIL-Dependent Manner
Several systemic autoimmune diseases have been postulated to
associate with viral infections (Getts et al., 2013). We hypothe-
sized that by restraining the CD4+ T cell response during
MCMV infection, NK cells may reduce the chance of autoimmu-
nity developing. We therefore analyzed the generation of autoan-
tibodies in WT and TRAIL-deficient mice and found that after
MCMV infection TRAIL-deficient mice had higher serum con-
centrations of antibodies reactive against proteins present in
SG homogenates (Figure 6A), suggesting that they may be
developing an autoimmune disease affecting this organ. Sjog-
ren’s syndrome (SS) is the secondmost common systemic auto-
immune disease. The disease affects salivary and lacrimal
glands and leads to exocrine dysfunction characterized by the
loss of saliva and tear production (Mavragani andMoutsopoulos,
2010). SS is characterized by focal lymphocytic infiltration into
the glands and the formation of aggregates resembling ectopic
germinal center-like structures in exocrine tissues (Bombardieri
and Pitzalis, 2012). Histological examination of SGs from WT
and TRAIL-deficient mice revealed the presence of lymphocytic
aggregates from day 40 postinfection. These structures were
very different from the disseminated lymphocytic infiltration
observed during the viremic phase of SG infection (up to day
32) (data not shown) and were found up to 120 days postinfec-
tion and localized around acini and ducts (Figure 6B). These
data demonstrate that MCMV infection leads to an inflammatory
response in SGs of TRAIL-deficient mice that has the histopath-
ological hallmarks of SS.
A key feature of SS is the production of autoantibodies,
in particular anti-Ro/SSA and anti-La/SSB (Kyriakidis et al.,
2014). Production of these autoantibodies was assessed using
a specific mouse ELISA. Anti-Ro antibodies were detected in
the sera of MCMV-infected mice from day 40 postinfection,
and titers were significantly higher in sera collected from infected
TRAIL-deficient mice compared to infected WT mice at all the
time points tested (Figure 6C). These data demonstrate that
the production of autoantibodies associated with SS is pro-
moted by viral infection and is limited by a TRAIL-dependent
mechanism.
Ultimately, the principal defect in SS is the inability to produce
saliva and tears. Saliva secretion wasmeasured after pilocarpine
stimulation in age-matched WT and TRAIL-deficient mice in-
fected with MCMV. At day 80 postinfection, there was a signifi-
cant difference in saliva flow between WT and TRAIL-deficient
mice, the latter showing reduced saliva production (Figure 6D).
To confirm that TRAIL+ NK cells mediated the phenotype, weImmunity 41, 646–656, October 16, 2014 ª2014 Elsevier Inc. 649
Figure 3. TRAIL+ NK Cells Limit CD4+ T Cell Numbers in the SGs
(A) Immunofluorescence staining (320) of SGs from WT mice at day 18 after MCMV infection. aNKp46 (red) and aCD4 (green) were used to stain NK and CD4+
T cells, respectively. NK cells per field were enumerated, and the number of NK cells in contact with CD4+ T cells determined. Data from 11 representative fields
from 3 individual mice are plotted as mean ± SEM. Data are representative of 3 independent experiments, each with at least 3 mice.
(B) Expression of DR5 on CD4+ T cells harvested from the SGs at various times after MCMV infection. Data are representative of four independent experiments
with at least three mice/time point.
(C) Number of CD4+ T cells in the SGs of WT and Trail–/– mice at various times after MCMV infection. Data are pooled from at least two independent experiments
with at least three mice/group and plotted as mean ± SEM (n = 7 or greater for both WT and Trail–/–).
(D) Number of DR5+CD4+ T cells in the SGs ofWT and Trail–/–mice at various times after MCMV infection. Data are pooled from two independent experiments with
at least three mice/group and plotted as mean ± SEM (n = 7–8 per time point).
(E) Expression of DR5 and CD44 on CD4+ T cells harvested from the SGs of WT mice at day 18 postinfection. Top panel shows a fluorescence minus one (FMO)
control. The data are representative of two independent experiments with at least three mice.
(legend continued on next page)
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Figure 4. NKG2D Is Expressed on TRAIL+
NK Cells and NKG2DL on DR5+CD4+ T Cells
(A) Frequency of SG NK cells expressing NKG2D
after MCMV infection was measured by flow cy-
tometry. The histogram depicts NKG2D expres-
sion on TRAIL+ NK cells at day 18 pi (open black
line) versus a FMO control for NKG2D (gray filled
histogram).
(B) The percentages of TRAIL+ and TRAIL NK
cells expressing high amounts of NKG2D are
shown. Data are pooled from two independent
experiments (n = 8) and plotted as mean ± SEM.
(C) Expression of NKG2D ligands on CD4+ and
CD8+ T cells is shown in representative FACS
plots. Analysis was performed on SG lymphocytes
isolated at day 18 post-MCMV infection, using a
mouse NKG2D-Fc fusion protein.
(D) The percentages of CD4+ and CD8+ T cells
expressing NKG2D ligands (NKG2DL) are shown.
Data are plotted as mean ± SEM from one exper-
iment (n = 3) and are representative of results from
three independent experiments.
(E) The expression of NKG2DL and CD44 on SG
CD4+ T cells is shown together with the frequency
of cells expressing DR5 within the NKG2DL-posi-
tive and NKG2DL-negative fractions of the
CD44hiCD4+ T cell pool. Cells were isolated from
the SGs of mice infected with MCMV (day 18).
Immunity
NK Cells Balance Viral Persistence and Autoimmunitydepleted NK cells from MCMV-infected mice from day 9 after
infection and then measured saliva production as above. As
noted in the absence of TRAIL, in the absence of NK cells,
MCMV-infected WT mice showed decreased saliva produc-
tion compared to WT mice with an intact NK cell response
(Figure 6E).
In addition to the SGs, SS affects the functionality of lacrimal
glands, and exocrine dysfunction in this tissue results in loss of
tear production. In MCMV-infected WT mice depleted of NK
cells, tear production was significantly reduced compared to un-
depleted WT controls (Figure 6F).
Altogether these data demonstrate that after MCMV infection,
mice lacking TRAIL on NK cells develop an autoimmune disease
with histopathological, clinical, and physiological features of SS.(F) Expression of DR5 and CD107a on CD4+ T cells harvested from the SGs of WT mice at day 18 postinf
uninfected mouse. The data are representative of two independent experiments with at least three mice pe
(G) Number of CD4+ T cells expressing DR5 and CD44hi in the SGs of WT and Trail–/– mice at day 18 pi. Da
(H) Number of CD4+ T cells expressing DR5 and CD107a in the SGs of WT and Trail–/– mice at day 18 pi. Da
*p < 0.05 obtained using a two-tailed Mann-Whitney test in (C), (D), and (H). *p < 0.05 obtained using a two
Immunity 41, 646–656DISCUSSION
Our data provide clear evidence for the
influence of NK cells on the adaptive im-
mune response to chronic viral infection
in a nonlymphoid tissue. NK cells specif-
ically accumulate in the SGs as part of
the local inflammatory response to infec-
tion, and a significant proportion express
TRAIL. TRAIL was originally identified on
the basis of its homology with TNF andits capacity to induce apoptosis in tumor cells (Wiley et al.,
1995). TRAIL mediates its apoptotic effects via specific death
receptors that are typically absent from normal cells and tis-
sues. Thus, TRAIL-deficient mice exhibit increased susceptibil-
ity to both tumor initiation and metastasis (Almasan and Ashke-
nazi, 2003; Takeda et al., 2001), leading to the widely held view
that the primary function of TRAIL is specific elimination of
transformed cells during innate immune surveillance. However,
TRAIL regulates the survival of a variety of other cell types,
including cells of the immune system that upregulate TRAIL re-
ceptors when activated (Falschlehner et al., 2009). A partial role
for NK cell TRAIL in eliminating hepatitis B virus-specific CD8+
T cells has been reported, but the study was not developed
beyond an in vitro system (Peppa et al., 2013). By contrast,ection. The top panel shows a FACS plot from an
r group (n = 7).
ta are plotted as mean ± SEM (n = 3 per group).
ta are pooled as mean ± SEM (n = 7–8 per group).
-tailed t test in (G).
, October 16, 2014 ª2014 Elsevier Inc. 651
Figure 5. TRAIL+ NK Cells Limit CD4+ T Cell
Numbers and Affect Chronic Viral Loads
(A) Viral loads in the SGs ofMCMV-infectedmice at
day 25 pi. Trail–/– mice were depleted of CD4+
(500 mg GK1.5 mAb at day 9, followed by 250 mg at
days 11, 16, and 20) or CD8+ (200 mg 53.5.8mAb at
day 9, followed by 100 mg at days 11, 16, and 20)
T cells. *p < 0.05, ns = not significant; obtained
using a one-way ANOVA with Tukey’s multiple
comparison test.
(B–D) Viral loads (B), frequency of DR5+CD4+
T cells (C), and number of DR5+CD4+ T cells (D) in
the SGs of MCMV-infected mice at day 25 pi. WT
mice (BALB.B6-CT6: H-2d, Ly49Hneg, NK1.1pos)
were infected with MCMV-K181 and NK cells
depleted with 200 mg PK136 on days 9, 13, 17, and
22 pi. Data are pooled from two independent ex-
periments for viral loads (B, nR 8) and from three
independent experiments for enumeration of
DR5+CD4+ T cells (C, D, n = 12).
(E) WT or Trail–/– mice that received 3–3.5 3 106
naive WT or Trail–/– NK cells i.v. on day 4 pi were
sacrificed on day 25 pi, together with control
MCMV-infected WT and Trail–/– mice, and viral ti-
ters were assessed by plaque assay. WT n = 11,
WT +WT NK cells n = 13, Trail–/– n = 8, Trail–/–+WT
NK cells n = 16, Trail–/–+ Trail–/– NK cells n = 5.
(F) Trail–/–mice that received 3–3.53 106 naive WT
or Trail–/–NK cells i.v. on day 4 pi were sacrificed on
day 25 pi and the number of CD4+DR5+ T cells in
the SGs enumerated (n = 3).
Data are plotted as mean ± SEM; *p < 0.05, **p <
0.01, ns = not significant; p values were obtained
using a one-tailed Mann-Whitney test (B–E) or a
one-tailed t test (F).
Immunity
NK Cells Balance Viral Persistence and Autoimmunityour work clearly demonstrates NK cell-dependent, TRAIL-medi-
ated killing of a physiologically important CD4+ T cell population
in vivo, which results in limiting antiviral responses to curb the
development of autoimmunity.
The elimination of activated CD4+ T cells from the SGs by NK
cells in a TRAIL-dependent manner resembles the elimination of
activated neutrophils by NK cells, where TRAIL expression is
crucial for the resolution of local inflammation (McGrath et al.,
2011). Thus, the expression of TRAIL by NK cells may serve as
a general mechanism by which NK cells limit the persistence of
activated cells at sites of inflammation and infection, to
encourage the resolution of the response. Notably, administra-
tion of recombinant TRAIL in a model of bacterial meningitis
decreased inflammation, as well as apoptosis, suggesting that
TRAIL may act as a potential anti-inflammatory agent (Hoffmann
et al., 2007).
Autoimmunity develops during MCMV infection that affects
the heart and SGs and is mediated by cross-reactive autoanti-
bodies (Bartholomaeus et al., 1988; Lawson et al., 1992). In the652 Immunity 41, 646–656, October 16, 2014 ª2014 Elsevier Inc.absence of TRAIL expression, we found
elevated titers of autoantibodies against
the SGs compared to WT controls. Previ-
ous studies have shown that TRAIL influ-
ences the development and severity of
several autoimmune diseases by eithermoderating the inflammatory response or by contributing to
the resolution of local inflammation (Lamhamedi-Cherradi
et al., 2003; Martinez-Lostao et al., 2012; Song et al., 2000).
Here, we show that TRAIL on NK cells influences the develop-
ment of a SS-like disease. The disease that develops in
MCMV-infected mice lacking either TRAIL or NK cells has all
the hallmark features of human SS, including the presence of
periductal lymphocytic aggregates in the SGs, an increased
incidence of anti-Ro/SSA autoantibodies (which are found in
>50% of SS patients), and reduced saliva and tear production.
As such, this mouse model shows the most extensive combina-
tion of histopathological, clinical, and physiological features of
human SS, and thus provides unique insights into the patho-
physiology of this important and highly prevalent autoimmune
disease.
The role of NK cells in autoimmunity has been controversial
(Shi and Van Kaer, 2006). One concept is that NK cells
amplify immune responses required to control transformed or in-
fected cells, and in doing so generate nonspecific damage to
Figure 6. Autoimmunity after MCMV Infec-
tion Develops More Rapidly in the Absence
of TRAIL Expression
(A) IgM autoantibodies reacting against SG ho-
mogenates from day 40 MCMV-infected WT and
Trail–/– mice. Data are pooled from two indepen-
dent experiments (n = 8).
(B) SGs from WT and Trail–/– mice at day 120 after
MCMV infection were examined histologically.
Black arrowheads denote the aggregates (scale
bars represent 200 mm, 203magnification). Images
from H&E-stained sections are representative of
results obtained in two independent experiments
with three to five mice/group.
(C) Anti-SSA antibody concentrations (IgG+IgA+
IgM) in sera of naive and MCMV-infected WT and
Trail–/– mice on days 40, 60, and 80 pi was as-
sessed by ELISA. Data are pooled from up to four
independent experiments (d0 n = 4, d40 n = 12,
d60 n = 18, and d80 n = 9 for each strain) and
plotted as mean ± SEM.
(D) Saliva flow in WT and Trail–/– mice at day 80
after MCMV infection. Data are plotted as mean ±
SEM (n = 6/group). **p < 0.01 was obtained using a
one-tailed Mann-Whitney test.
For (A) and (D), *p < 0.05, obtained using a one-
tailed unpaired t test withWelch’s correction, since
the data had a normal distribution.
(E) Saliva flow at 72 days after MCMV infection in
control and mice depleted of NK cells with 200 mg
PK136 on days 9, 13, 17, and 22 pi. Data are
plotted as mean ± SEM (n = 3/group). *p < 0.05,
obtained using a one-tailed t test.
(F) Tear production at 71 days after MCMV infec-
tion in control and mice depleted of NK cells with
200 mg PK136 on days 9, 13, 17, and 22 pi. Data are
plotted as mean ± SEM (n = 4/group). ***p < 0.001
was obtained using a one-tailed t test.
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immune disease. Consistent with this, a recent study found an
accumulation of NK cells in the SGs of patients with primary
SS (pSS) and defined a genetic polymorphism within the
NKp30 promoter that associated with the severity of pSS (Rusa-
kiewicz et al., 2013). Since NKp30 is an activating receptor, the
authors proposed that NK cells promote pSS and that blocking
its activation may be therapeutic. However, our findings demon-
strate that there may be an alternative explanation for the accu-
mulation of NK cells in the SGs, and blocking NK cell function
may exacerbate, rather than ameliorate, pSS. Regardless, Rusa-
kiewicz’s study establishes two important points: (1) NK cells ac-
cumulate in the SGs during pSS, correlating with the severity of
disease, and (2) an activating NK cell receptor is associated with
the development of autoimmunity. More work will be required to
elucidate the role of NK cells in the pathogenesis of pSS, but our
results argue that there is an alternate role for NK cells in limiting
the development of autoimmunity.
Our results indicate that, in the context of MCMV-induced
autoimmunity, autoreactivity is constrained through the elimina-
tion of CD4+ T cells by TRAIL-expressing NK cells. It is not yet
clear whether it is solely the antiviral CD4+ T cells that are elimi-
nated by TRAIL+ NK cells, or whether bystander CD4+ T cells are
also affected. Unfortunately, MCMV-specific epitopes for CD4+T cells have not been defined. However, the differences
observed in viral loads in WT versus TRAIL-deficient mice argue
that TRAIL+ NK cells do indeed eliminate MCMV-specific CD4+
T cells. In this respect, our data support a model where antiviral
CD4+ T cells initiate autoimmunity by releasing autoantigens
through the elimination of MCMV-infected SG cells.
These findings reveal a novel and unexpected capacity of NK
cells, a prototypical innate lymphocyte population, in the context
of chronic viral infection. Furthermore, they highlight novel inter-
plays between NK cells and T cells. On one hand, an effector
CD4+ T cell population is crucial for control of chronic viral infec-
tion, but on the other, a population of NK cells acts to specifically
eliminate these T cells, thereby reducing autoimmunity. The deli-
cate balance of tissue homeostasis with control of a chronic viral
pathogen highlights the mechanisms that may be at play in sys-
temic autoimmune diseases with a viral etiology.
EXPERIMENTAL PROCEDURES
Mice and MCMV Infection
BALB/c (H-2d, I-Ad, NK1.1–, Ly49H–), BALB.B6-CT6 (CT6) (H-2d, I-Ad, NK1.1+,
Ly49H–) (Scalzo et al., 1999), TRAIL-deficient BALB/c (Trail–/–) (van der Most
et al., 2009), and DR5-deficient BALB/c (Dr5–/–) mice were bred at the Animal
Resources Centre (Perth, Australia), the Animal Service Facility of the Uni-
versity of Western Australia (UWA), and the Peter MacCallum Cancer CentreImmunity 41, 646–656, October 16, 2014 ª2014 Elsevier Inc. 653
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NK Cells Balance Viral Persistence and Autoimmunity(Melbourne, Australia). Mice were maintained in specific-pathogen-free condi-
tions. All animal experimentation was conducted with the approval of the UWA
Animal Ethics and Experimentation Committee, in accordance with the guide-
lines of NHMRC Australia. Mice were inoculated intraperitoneally (i.p.) with 13
104 plaque-forming units (PFUs) of SG-propagated MCMV-K181Perth, except
for flow cytometric analyses where the inoculum was reduced to 5 3 103
PFU. Mice (8–14 weeks old) were used for all experiments and were randomly
allocated into treatment groups.
Flow Cytometry and Intracellular Cytokine Staining
Cell isolation and staining was performed according to standard protocols.
Lymphocytes were stained with mAbs specific for CD3 (145-2C11), TCRb
(H57-597), CD4 (RM4-5), CD8 (53-6-7), DR5 (MD5-1), CD19 (1D3), NKp46
(29A1.4), NK1.1 (PK136), CD44 (IM7), CD49b (DX5), CD122 (TM-b1), TRAIL
(N2B2), CD11b (M1/70), CD11c (N418 or H3L), CD27 (LG7F9), CD43 (S7),
CD62L (MEL-14), CD69 (H1-2F3), Ly6C (AL 21), KLRG1 (2F1), NKG2D
(191004 from R&D Systems), and recombinant mouse NKG2D-Fc fusion pro-
tein (R&D Systems). Degranulating cells were detected by culturing cells in the
presence of anti-CD107a mAb (ID4B) and 5 mg/ml monensin sodium salt
(Sigma-Aldrich) for 4 hr before surface staining. Biotinylated antibodies were
detected with streptavidin (SA)-conjugated flurochromes. Antibodies were ob-
tained from BD Biosciences, BioLegend, or eBioscience, unless otherwise
noted.
Measuring MCMV Growth In Vivo
Tissues were homogenized in MEM buffer supplemented with 2% NCS.
Homogenates were centrifuged at 3,000 rpm for 15 min at 4C, and super-
natants were collected and stored at –80C. Viral titers were quantified by
plaque assay using M210B4 fibroblast monolayers (Ong et al., 2013); in brief,
serial dilutions of viral supernatants were performed in MEM+2% NCS and
transferred onto a subconfluent M210B4 cell monolayer in 24-well tissue
culture trays (BD Biosciences). Trays were incubated at 37C for 1 hr
before removing the supernatant and overlaying cells with 1 ml of 0.01%
carboxy-methylcellulose (CMC; Sigma-Aldrich) diluted 1:2 in MEM+2%
NCS. Trays were incubated at 37C/5% CO2 for 4 days, fixed, and stained
with 0.5% methylene blue in 10% formaldehyde for 1 day at RT. Plaques
in the M210B4 monolayer were counted and numbers of plaques per organ
calculated.
In Vivo Treatments
CD4+ or CD8+ T cell depletion was achieved by administering 500 mg/mouse of
CD4-specific mAb (GK1.5) or 200 mg/mouse of CD8b-specificmAb (53.5.8) i.p.
on day 9 pi, followed by i.p. injection of 250 mg anti-CD4 or 100 mg anti-CD8 on
days 11, 16, and 20 pi. To deplete NK cells, CT6 mice were treated i.p. with
200 mg/mouse of anti-NK1.1 mAb (PK136) on days 9, 13, 17, and 22 pi. Deple-
tion of CD4+ T cells, CD8+ T cells, or NK cells was confirmed by flow cytometric
analysis.
Adoptive NK Cell Transfer
Splenocytes were isolated from either naive CT6 or Trail–/– mice and purified
using a nylon wool column (LEUKO-PAK Leukocyte Filter; Fenwal) (Eisen
et al., 1972). The purified cell suspension was further enriched for NK cells
with a mouse NK cell enrichment kit (StemCell Technologies) according to
the manufacturer’s instructions. NK cell purity, as assessed by flow cytometry,
was >90%. BALB/cWT and Trail–/– mice received 3–3.53 106 cells per mouse
of the NK cell-enriched suspension on day 4 pi by intravenous (i.v.) injection in
the retro-orbital sinus.
Immunohistochemistry
SGs were excised and fixed as described (Andrews et al., 2001). Tissue sec-
tions (6 mm) were cut and stored at 20C. Sections were then quenched in
50 mM NHCl4 for 10 min, blocked for 1 hr in MOBS with 10% normal goat
serum (NGS) and 0.1%Triton X-100 (Sigma-Aldrich), and stained with PE-con-
jugated NKp46 (clone 29A1.4, Biolegend 12-3351-82) and biotinylated CD4
(clone RM 4-5, BD 553045) plus Alexa-Fluor488-conjugated SA (Invitrogen
S32354). Sections were analyzed with an epifluorescence microscope
(Olympus) and images collected with a digital camera (Olympus) at the magni-
fications indicated.654 Immunity 41, 646–656, October 16, 2014 ª2014 Elsevier Inc.Histological Analysis
SGs were excised and fixed and stained with hematoxylin and eosin. Sections
were analyzed with light microscope (Olympus) and images collected with a
digital camera (Olympus) at the magnifications indicated.
Autoantibody Testing
Tissue-Specific Autoantibody ELISA
Trays were coated with supernatant of homogenized tissues (1 hr at 37C,
overnight at 4C). Serum samples (1:25 dilution) were added for 1 hr. Plates
were then incubated with biotin-conjugated anti-mouse IgM antibody (Jack-
son ImmunoResearch Laboratories, 115-066-020) and SA-horse radish perox-
idase (HRP; Thermo Scientific N200) for 1 hr each. Values are shown as fold of
intensity increase in infected mice compared to naive mice.
Mouse Anti-SSA ELISA
Total anti-SSA Ig (IgG+IgA+IgM) in the serum was assessed using an ELISA kit
from Alpha Diagnostic International (kit 5710) according to manufacturer’s in-
structions. Plates were read with a SpectraMax ELISA reader (Molecular
Devices).
Measuring Saliva Flow and Tear Production
Mice were injected with pilocarpine (50 mg/100 g body weight) and after 5 min,
saliva was collected using a sterile cotton swab. The swabwasweighed before
and after saliva collection and the amount of saliva collectedwas normalized to
mg saliva per g of body weight. Tear production was assessed by holding a
sterile phenol red thread (Tianjin Jingming New Technological Development
Co.) in the lateral canthus of the eye. After one minute, tear production was
measured as mm of color change on the indicator thread.
Experimental Design and Statistical Analysis
Sample sizes of at least threemice (n = 3–6) per experimental group were used
and experiments were repeated as noted to ensure appropriate representation
of experimental data, as well as reproducibility. All data were analyzed and
graphed using Prism (GraphPad Software). Statistical significance was deter-
mined by the nonparametric Mann-Whitney test. An ANOVA with Tukey’s
post-test was used when more than two groups were compared. A t test
was used for data showing a normal distribution. Welch’s correction was
used for comparison between groups with unequal variance. One-tailed statis-
tical tests were performed if the assumption that the difference between
groups could only go in one direction was valid based on previous studies.SUPPLEMENTAL INFORMATION
Supplemental Information includes two figures and can be found with this
article online at http://dx.doi.org/10.1016/j.immuni.2014.09.013.
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